Dermatitis: Clinical Trials

15 trials for Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 terminated. 15 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 315Terminated 15
Phase 23Terminated 3

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Rocatinlimab, Placebo - Atopic Dermatitis
Phase 3TerminatedAmgen26212023-05-312026-07-16
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified
Phase 2 / Phase 3TerminatedPfizer582023-01-182025-05-08
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream - Pruritus, Atopic Dermatitis
Phase 3TerminatedCara Therapeutics, Inc.2872022-08-162024-02-22
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
Application of Tralokinumab - Atopic Dermatitis
Phase 2 / Phase 3TerminatedUniversity of Zurich242022-06-152026-02-06
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
Crisaborole 2% - Atopic Dermatitis
Phase 3TerminatedPfizer402020-09-142021-08-12
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
Tradipitant, Placebo - Atopic Dermatitis
Phase 3TerminatedVanda Pharmaceuticals872019-10-212024-05-14
Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema
Fucicort® Lipid cream, Fucidin® cream, Fucicort® Lipid cream vehicle - Infected Atopic Dermatitis/Eczema
Phase 3TerminatedLEO Pharma682018-07-312025-02-24
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
Baricitinib - Atopic Dermatitis
Phase 3TerminatedEli Lilly and Company3742018-06-272022-11-08
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
5 mg Serlopitant Tablets - Pruritus, Prurigo Nodularis
Phase 3TerminatedVyne Therapeutics Inc.5582018-03-152021-05-20
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
AIN457, Placebo - Non-infectious Uveitis
Phase 3TerminatedNovartis Pharmaceuticals862010-08-012016-01-14
Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children
Fluticasone, cream, Placebo, - Dermatitis, Atopic
Phase 3TerminatedElena Rubio Gomis542009-12-012015-01-09
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
pyridoxine hydrochloride, Placebo - Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Phase 3TerminatedNational Cancer Centre, Singapore2102007-06-012015-09-24
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
Capecitabine, Celecoxib, Radiation Therapy - Breast Cancer, Colorectal Cancer
Phase 3TerminatedM.D. Anderson Cancer Center112006-02-012015-12-24
Lamictal in the Treatment of Post-Herpetic Neuralgia
Lamictal in the treatment of Post-Herpetic Neuralgia - Neuralgia, Postherpetic
Phase 2 / Phase 3TerminatedGeorge Washington University2005-02-012013-03-13
Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients
Skin Biopsy - Dermatitis
Phase 3TerminatedHordinsky, Maria K., MD302002-11-012013-02-05

Narrower conditions

Dermatitis, Atopic (9)  ·  Eczema (7)  ·  Hand-Foot Syndrome (2)  ·  Pruritus (2)  ·  Psoriasis (2)  ·  Breast Neoplasms (1)  ·  Breast Neoplasms, Male (1)  ·  Cardiovascular Diseases (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Myocardial Infarction (1)  ·  Neuralgia, Postherpetic (1)  ·  Pain (1)

Broader conditions

Skin Diseases (15)  ·  Skin and Connective Tissue Diseases (15)  ·  Hypersensitivity (10)  ·  Immune System Diseases (10)  ·  Skin Diseases, Eczematous (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)  ·  Genetic Diseases, Inborn (9)  ·  Hypersensitivity, Immediate (9)  ·  Skin Diseases, Genetic (9)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Signs and Symptoms (4)  ·  Chemically-Induced Disorders (3)  ·  Drug Eruptions (3)  ·  Drug Hypersensitivity (3)

Interventions

Betamethasone (1)  ·  Capecitabine (1)  ·  Celecoxib (1)  ·  Fluticasone (1)  ·  KHK4083 (1)  ·  Lamotrigine (1)  ·  Pyridoxine (1)  ·  Radiotherapy (1)  ·  baricitinib (1)  ·  difelikefalin (1)  ·  etrasimod (1)  ·  secukinumab (1)  ·  serlopitant (1)

Sponsors

Pfizer (2)  ·  Amgen (1)  ·  Cara Therapeutics, Inc. (1)  ·  Elena Rubio Gomis (1)  ·  Eli Lilly and Company (1)  ·  George Washington University (1)  ·  Hordinsky, Maria K., MD (1)  ·  LEO Pharma (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Cancer Centre, Singapore (1)  ·  Novartis Pharmaceuticals (1)  ·  University of Zurich (1)  ·  Vanda Pharmaceuticals (1)  ·  Vyne Therapeutics Inc. (1)

Countries

United States (10)  ·  Canada (3)  ·  Germany (3)  ·  Poland (3)  ·  Puerto Rico (3)  ·  Spain (3)  ·  Switzerland (3)  ·  Austria (2)  ·  Brazil (2)  ·  China (2)  ·  Czechia (2)  ·  Israel (2)  ·  Japan (2)  ·  Singapore (2)  ·  United Kingdom (2)

Top investigators

Elena Rubio Gomis, PhD MD (1)  ·  Maria Hordinsky, MD (1)  ·  Perry K. Richardson, M.D. (1)  ·  Peter Schmid-Grendelmeier, Prof, MD (1)  ·  Scott Kopetz, MD (1)  ·  Yoon-Sim Yap, FRACP, MBBS (1)

Results publications

PMID 28715540, PMID 33826132, PMID 36749121

NIH funding

2008 (1), 2009 (1), 2017 (1)